A patient with a diagnosed gastrointestinal malignancy is being followed up using a tumor marker to monitor recurrence and treatment response. The clinician orders carcinoembryonic antigen (CEA) levels.
In which malignancy is CEA most commonly used?
Decoding the Stem
Detailed Explanation
✅ Correct Option (Colonic Carcinoma): Carcinoembryonic Antigen (CEA) is a glycoprotein involved in cell adhesion. While it is produced during fetal development and disappears after birth, it reappears in certain malignancies. It is most classically used as a tumor marker for colorectal carcinoma to monitor for recurrence and assess treatment response.
❌ Why other options are incorrect:
→ Testicular tumor: Markers include AFP (yolk sac component), β-hCG (choriocarcinoma/seminoma), and LDH.
→ Ovarian carcinoma: Primarily followed with CA-125.
→ Pancreatic carcinoma: Primarily followed with CA 19-9.
→ Malignant melanoma: No specific diagnostic serum tumor marker; LDH is used for prognosis.
🧠High-Yield Pearls
Integrated Clinical Questions
1. Tumor marker for hepatocellular carcinoma?
2. Tumor marker for prostate cancer?
3. Tumor marker for pancreatic cancer?
4. Tumor marker for ovarian cancer?
5. Limitation of CEA?
⚡ Exam Pearls
- • CEA = colon cancer (most tested association).
- • Not for screening → only used for follow-up and treatment monitoring.
- • Always match: Tumor ↔ marker for common exam MCQ sets.
0 Comments